Rosiglitazone promotes oligodendrocyte development and myelin formation of repeated neonatal sevoflurane exposure via PPARγ signaling

Abstract

One of the most prevalent general anesthetics for kids and infants is sevoflurane. According to recent research, repeated exposure to sevoflurane in neonates induces cognitive and motor deficits. Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have drawn plenty of attention recently as possible therapies for a variety of neurological conditions. In this research, we evaluated whether pretreatment with rosiglitazone in neonatal mice can repair myelination defects, cognitive impairment, and motor dysfunction via PPARγ. The mice were treated with 3% sevoflurane for two hours on postnatal days 6–8. The behavioral tests were conducted from P29 to P34. Additionally, we evaluated morphological and functional symptoms related to myelin.Our results showed that rosiglitazone pretreatment significantly ameliorated the cognitive and motor impairments of repeated neonatal sevoflurane exposure. Meanwhile, rosiglitazone pretreatment promoted oligodendrocyte precursor cell (OPCs) differentiation and myelination.This suggests that rosiglitazone may be used in clinical settings to increase the security of neonatal sevoflurane exposure. Furthermore, PPARγ and FASN may be mediators of rosiglitazone, which alleviates myelination defects, cognitive impairment, and motor dysfunction.